The Motley Fool: An inside look at Amgen’s fall - Dallas …

Personal Finance | Dallas Morning NewsBusiness | Page 2 | Dallas Morning NewsMoney | Dallas Morning News

3%
OFF

Down 12.3% At One Point In A Single Trading Session ... - The …

2 weeks from now

Nov 30, 2024 · The market didn't appreciate Amgen's (AMGN-0.26%) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous …

fool.com

6%
OFF

Is Amgen Stock Still A Buy After An Unexpected Reveal Of Data?

2 weeks from now

Nov 29, 2024 · Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially …

sharewise.com

20%
OFF

Is Amgen Stock A Buy? - Yahoo Finance

2 weeks from now

Oct 18, 2024 · Premium News. Earnings. Tech. Housing. Crypto. Markets. ... The Motley Fool . Fri, Oct 18, 2024, ... Amgen's product net sales climbed by 20% year over year with 12 drugs …

yahoo.com

7%
OFF

2 Reasons To Buy Amgen Stock, And 1 Reason To Be Cautious

2 weeks from now

Nov 16, 2024 · While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, …

yahoo.com

37%
OFF

Is Amgen Still A Top Dividend Stock? | The Motley Fool

2 weeks from now

Dec 5, 2024 · Amgen's shares have slipped 3.37% in 2024 despite the S&P 500's 26.8% surge, creating a potential value opportunity. Recent pipeline setbacks mask a cash-generating …

fool.com

75%
OFF

Is Amgen Stock A Buy Now? - The Motley Fool

2 weeks from now

Oct 20, 2022 · Shares of Amgen (AMGN-0.75%) have been rising of late after a recent analyst upgrade generated some bullishness around the biotech company. Year to date, the stock is …

fool.com

20%
OFF

Where Will Amgen Be In 5 Years? - The Motley Fool

2 weeks from now

Sep 20, 2024 · Amgen's organic revenue hasn't been growing particularly fast recently. In the second quarter, the company's top line grew 20% year over year to $8.4 billion, a performance …

fool.com

$1
OFF

What This News Might Mean For Amgen | The Motley Fool

2 weeks from now

Aug 31, 2022 · This treatment is also Amgen's only drug to make Medicare's top 10 drugs by sales, coming in near the top of the Part B list with $1.6 billion in 2020 government sales.

fool.com

04%
OFF

Amgen's Beating The Market -- Here's Why It's A Buy Now - The …

2 weeks from now

Jul 1, 2022 · Amgen (AMGN 3.04%) is the world's largest biotechnology company by revenue, focusing on using living cells to create a robust product portfolio of biologic medicines to treat …

fool.com

10%
OFF

Why Auto Stock Magna International Fell Over 10% Today

2 weeks from now

5 days ago · The shares of Magna International (MGA-6.35%) plunged 11.6% this morning as panic gripped investors after President Donald Trump announced plans to impose hefty import …

fool.com

FAQs about The Motley Fool: An inside look at Amgen’s fall - Dallas … Coupon?

What happened to Amgen's stock on Wednesday?

The stock of veteran biotech Amgen ( AMGN -0.55%) was looking a little tired on Wednesday. The company's shares fell more than 2% in price, "thanks" to fourth-quarter results that didn't put smiles on investors' faces. In contrast to gloomy Amgen, the S&P 500 index ticked up by slightly more than 1%. ...

Did Amgen's 'undisclosed' clinical data look favorable to investors?

Investors recently learned about undisclosed data from one of Amgen's clinical trials. The new information didn't look favorable at first glance. ...

Is Amgen a good entry point for a long-winded rate-cutting cycle?

Amgen (AMGN 0.49%) offers an intriguing test case for this dynamic heading into 2025. The biotech-giant's shares have slumped 3.37% in 2024, while the S&P 500 has surged 26.8% as of this writing, creating what might be a compelling entry point ahead of what could prove to be a long-winded rate-cutting cycle. Image source: Getty Images. ...

Who is the Motley Fool?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. ...

Should Amgen develop a drug that would beat the incumbents?

So, Amgen has an opening to develop a drug that would beat the incumbents if its candidate excels in (at least) one of three areas: efficacy in causing weight loss, convenience in dosing, or tolerability (side effects). ...